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ABSTRACT 
 
Adrenocortical carcinoma (ACC) is a devastating tumor for either patients or their families 
because of short life expectancy and severe impact on quality of life. Due to the rarity of ACC, with 
a reported annual incidence of 0.5–2 cases per million population, progress in the development of 
treatment options beyond surgery has been limited. Up to now, no personalized approach of ACC 
therapy has emerged, apart from plasma level - guided mitotane therapy, and no simple targetable 
molecular event has been identified from preclinical studies. Complete surgical removal of ACC is 
the only potentially curative approach and has the most important impact on patient’s prognosis. 
Despite the limits of the available evidence, adjuvant mitotane therapy is currently recommended in 
many expert centers whenever the patients presents an elevated risk of recurrence. The management 
of patients with recurrent and metastatic disease is challenging and the prognosis if often poor. 
Mitotane monotherapy is indicated in the management of patients with a low tumor burden and/or 
more indolent disease while patients whose disease show an aggressive behavior need cytotoxic 
chemotherapy. The treatment of patients with advanced ACC may include loco-regional approaches 
such as surgery and radiofrequency ablation in addition to systemic therapies. The present review 
provides an updated overview of the management of ACC patients following surgery and of the 
management of ACC patients with advanced disease. 
 
 
 
 
 
 
INTRODUCTION 
Adrenocortical carcinoma (ACC) is a devastating tumor for either patients or their families 
because of short life expectancy and severe impact on quality of life, that is severely affected by 
metastatic progression, associated endocrine syndromes and treatment-related side effects. The fact 
that ACC has a first peak of incidence in young children and frequently occurs in women of 
childbearing age makes the management of this aggressive tumor even more challenging. In 
addition, currently available treatments of advanced ACC have limited efficacy and relevant 
toxicity that concurs to reduce quality of life (1-3). 
Due to the rarity of ACC, with a reported annual incidence of 0.5–2 cases per million population 
(4, 5), progress in the development of treatment options beyond surgery has been limited. Up to 
now, no personalized approach of ACC therapy has emerged, apart from plasma level - guided 
mitotane therapy, and no simple targetable molecular event has been identified from preclinical 
studies. Although generally regarded as one of the most aggressive endocrine tumors, ACC may 
present with a heterogeneous biological behavior ranging from almost indolent to extremely rapidly 
progressing tumors. Therefore, prognostic stratification of patients is of the utmost importance to 
tailor the treatment plan accordingly. However, we have limited knowledge of pathological and 
clinical criteria for risk stratification of ACC patients and the identification of prognostic and 
predictive biomarkers has to be actively pursued.  
Management of ACC patients is challenging and demanding because physicians have to deal 
with either oncological issues, concerning tumor progression and metastatic development, or 
endocrinological issues, related to tumor secretion or specific treatment (mitotane effects on the 
endocrine system).  Treatment of ACC is multi-modal, including surgery (often repeated), mitotane, 
cytotoxic agents, interventional radiology procedures, radiotherapy, and should be delivered by a 
multidisciplinary team within centers with adequate facilities (1-3, 6-8). 
The objectives of this review are: i) to provide an updated overview of the management of ACC 
patients following surgery; ii) to provide an updated overview of the management of ACC patients 
with advanced disease. It has to be pointed out that the recommendations of this review are 
generally based on a low level of evidence and may represent the personal view of the authors. 
MANAGEMENT OF ACC PATIENTS FOLLOWING SURGERY 
 
Background 
Complete surgical removal of ACC is the only potentially curative approach and has the most 
important impact on patient’s prognosis (1-3). Whether surgery should be done as open 
adrenalectomy or whether laparoscopic adrenalectomy may be safely performed in selected patients 
is matter of an ongoing debate (9-12). Despite this controversy, what is most important is that ACC 
surgery should be performed by experienced surgeons in referral centers with a high operation 
volume (7). A common finding of all surgical series is that recurrence after apparently complete 
resection is frequent and may be found in up to 70–85% of patients with high proliferation index or 
locally advanced disease (1-3, 8, 13-16). This observation makes a strong case for post-operative 
adjuvant treatment in ACC management.  
In early years, many investigators considered the use of post-operative adjuvant therapy due to 
the high recurrence rate of ACC. The adrenolytic drug mitotane, an analogue of the insecticide 
dichlorodiphenyltrichloroethane (DDT) widely used for advanced ACC since the sixties, was 
considered the reference drug also for adjuvant treatment. However, those studies provided 
conflicting results for a number of reasons, namely small patient numbers, lack of control groups, 
unclear specification of treatment outcome (17). Given the lack of convincing evidence of the 
benefit of adjuvant mitotane, enthusiasm for this approach declined and no recommendation on 
post-operative adjunctive measures was released at the Ann Arbor Consensus Conference on ACC 
in 2003 (13).  
In 2007, we published the results of a multicentric, retrospective analysis of post-operative 
management of 177 patients with ACC, who were recruited either at some centers in Italy where 
adjuvant mitotane was a standard following radical surgery or at other Italian centers where radical 
surgery was not followed by mitotane treatment. An independent cohort from Germany of patients 
who were not offered any post-operative treatment was also included. Recurrence-free survival 
(RFS) was significantly longer in the 47 patients treated with adjuvant mitotane, being 42 months 
versus 10 months and 25 months, respectively, in the two groups of 55 and 75 patients who were 
left untreated after surgery (18). Multivariate analysis confirmed that mitotane had an independent 
advantageous effect on RFS. The effect on overall survival (OS) was less apparent but nevertheless  
significant after adjusting for an imbalance of prognostic factors among the different groups (18). 
An important finding of the study is the acceptable adverse event rate, a finding that was likely due 
to the use of low doses of mitotane (1–5 g per day). Conversely, employment of high-dose mitotane 
in previous studies has been invariably accompanied by severe and disabling toxicity (17). 
Strengths of our study are a large patient cohort, availability of well-matched contemporary control 
groups, and predefined treatment allocation independent from patient’s characteristics. Given its 
retrospective nature, however, this study cannot provide a high level of evidence in favor of 
adjuvant mitotane treatment. The publication of that study renewed interest on the use of mitotane 
in an adjuvant post-operative setting but raised also a fierce controversy based on the 
methodological flaws of that study (19).  
Other adjunctive measures following surgical removal of ACC have received less attention. 
Cytotoxic agents have been rarely used in an adjuvant setting. The most interesting study is the one 
by Khan et al (20), who reported that 17 patients treated with the association of streptozotocin and 
mitotane had a significantly better RFS than 11 patients who did not receive any treatment after 
surgery. However, the study does not allow to discriminate the relative contribution of each drug. 
Despite the historical view that ACC is a radio-resistant tumor, the adjuvant use of radiotherapy has 
been explored in recent years. The argument remains conflicting, since two initial studies showed a 
significant reduction of local recurrences with radiation therapy, although the impact on RSF and 
OS was not fully clear (21, 22), while a more recent study did not show any benefit of adjuvant 
radiotherapy (23). Methodological differences among studies and the inevitable limits inherent to 
their retrospective nature may offer a reasonable explanation of this discrepancy.  
In recent years, the adjuvant use of mitotane has become increasingly popular and in current 
practice the management of an ACC patient operated on certainly includes the option of giving 
mitotane. Therefore, the present review will focus on the use of mitotane as an adjuvant measure. 
 
Selection of patients to adjuvant mitotane  
Despite the limits of the available evidence, adjuvant mitotane therapy is currently recommended  
in many expert centers whenever the patients presents an elevated risk of recurrence. Differences do 
exist in the criteria used to define a high-risk condition, as exemplified in a recent position of an 
international panel of experts who agreed on stage I-II, complete (R0) resection and ki-67 ≤ 10% as 
markers of good prognosis, but a consensus was not found on stage III R0 ACC (24). In patients 
with good prognostic markers, the decision on adjuvant mitotane therapy may be individualized, 
whereas adjuvant mitotane is mandatory in the high-risk category (24). Following the ENS@T 
ACC staging system, stage III applies to locally invasive tumors characterized by infiltration in 
surrounding tissue, positive regional lymph nodes or a neoplastic thrombus in the vena cava or vena 
renalis (25). It is biologically plausible that tumor spread in regional lymph nodes or in the vein 
system may portend to a higher risk of recurrence than local infiltration and it is our opinion that 
subgroups at different risk of recurrence do exist among stage III ACC. Infrequently, a stage IV 
ACC, defined by presence of distant metastases (25), may be completely resected and has to be 
considered at a high risk of recurrence. The lowest risk applies to stage I and II ACC, being tumors 
localized in the adrenal gland with a with a size of ≤5 cm or >5 cm, respectively (25). 
Recent data suggest that the proliferation activity of the tumor is the most important factor 
predicting risk of recurrence following R0 surgery. Assessment of the proliferation index Ki-67 is 
currently used to assess proliferation, despite some problems to harmonize immunohistochemical 
readings among different pathologists. In an European multicentric study, a threshold value at 10% 
was found to separate patients at good or worse prognosis with a hazard ratio of recurrence of 1.042 
per each % increase (26). Although the results of this study have still to be considered as 
preliminary, the availability of a large patient cohort totaling more than 500 patients represents a 
solid database to confirm the view that tumor proliferation is a strong determinant of patient 
survival. The value of ACC proliferation has been already appreciated in smaller series by the use 
of mitosis count (27, 28), that is likely the single most predictive factor of Weiss score. Conversely, 
Weiss score as a whole does not clearly indicate the probability of tumor recurrence (28, 29).  
Resection status is another established adverse risk factor, being Rx (unknown), R1 
(microscopically positive margins) and R2 (macroscopically positive margins) associated with 
progressively reduced RFS irrespectively of other risk factors (2-8).  
A number of molecular markers, like matrix metalloproteinase type 2 (30), glucose transporter 
GLUT1 (31), SF1 (32), BUB1B and PINK1 (33) might potentially emerge in the future as powerful 
outcome predictors, but none of them has yet found a place in current management of ACC. 
 
Management of patients on adjuvant mitotane treatment 
No results from randomized controlled trial on adjuvant mitotane treatment are available. We 
have recently launched the first prospective randomized study –the ADIUVO trial (NCT00777244)- 
which is currently recruiting at different European and North-American centers. The aim of this 
trial, whose results are not expected before 2016, is to compare the results of adjuvant mitotane with 
a strategy of no treatment on RFS (the study primary endpoint) in patients at low-intermediate risk 
of recurrence, defined by stage I to III ACC, R0 and Ki-67 ≤ 10% (www.adiuvo-trial.org). At our 
center, we are currently recommending low-risk patients to enter the trial while the remainders are 
offered adjuvant mitotane (Figure 1). Most patients seen in our practice actually belong to the high-
risk category and are candidate to mitotane, which is an off-label prescription in adjuvant setting.  
Whenever the decision of giving mitotane is taken, monitoring of plasma mitotane levels is 
currently considered a standard in the management of ACC patients treated adjuvantly because 
mitotane is known to have a narrow therapeutic window (1-3, 6, 17). The concept that plasma levels 
of mitotane matter for both therapeutic efficacy and drug-related toxicity has been developed in the 
clinical scenario of advanced ACC (34-36).  Mitotane concentration should be kept above 14 mg/l 
to achieve the most from treatment (36). The same target of 14 mg/l has been pursued by many 
experts also when using mitotane as an adjuvant measure, despite the lack of specific data in 
disease-free patients (1-3, 17). Results of a very recent retrospective analysis provided evidence that 
this strategy is sound also in the adjuvant setting (37). Of 122 ACC patients who were radically 
resected, 63 patients reached and maintained target mitotane concentrations during follow-up. They 
had a significantly lower rate of recurrence than 59 patients who failed to keep mitotane levels as 
high. Mitotane was an independent factor influencing RFS at a multivariate analysis while the 
prolongation of OS did not reach levels of statistical significance (37). This may be due to the 
relatively short follow-up duration and should not downplay the  effect of mitotane. The study 
actually provided a further, although indirect, evidence in favor to adjuvant mitotane. 
What is the best dosing regimen to initiate mitotane therapy is currently debated and either high-
dose or low-dose regimens are employed. A high-dose regimen has the merit of inducing a faster 
rise of plasma mitotane that may translate in a more rapid action of the drug (38, 39). It is 
concerning that several weeks of treatment are needed to attain blood drug levels conferring 
therapeutic efficacy (1-3, 17, 40), since this may cause a window of under-treatment following 
surgery during which tumor remnants may grow and progress. With a low dose regimen, a longer 
time needed to achieve therapeutic concentrations may be anticipated.  However, RFS did not differ 
between patients attaining target mitotane concentrations within 3 months and patients who did not 
in a retrospective study of 122 patients who underwent a monitored mitotane treatment (37). It is 
likely that a continuous maintenance of target mitotane concentrations during follow-up be of more 
importance that a faster attainment of desired levels. Furthermore, a high-dose regimen requires an 
intensive follow-up and may be more frequently associated with side effects, while a low dose 
regimen is better tolerated and easier to manage in an outpatient setting (1, 17).  
In our practice, we start mitotane treatment as soon as possible after surgery with 2 tablets (1 
gram) daily. The patient is instructed to add one tablet every 4-7 days, depending on drug 
tolerability, targeting a dose of 6–8 g daily, or the maximum tolerated dose. We try to accommodate 
mitotane schedule to patient’s tolerance with the aim of increasing compliance with treatment and 
minimizing the impact on patient’s quality of life. However, we are strongly committed to target 
serum mitotane concentrations of 14–20 mg/l. Monitoring of mitotane concentrations is done on a 
regular basis,  after 4 to 6 weeks from treatment start and thereafter every 4–8 weeks until target 
levels are reached to adjust dosage accordingly. Then, mitotane dose can be usually reduced and 
monitoring is done less frequently. We manage mitotane toxicity by reducing the daily dose to the 
previously tolerated one, or discontinuing treatment for a while allowing resolution of complaints. 
Mitotane monitoring is key for the management of patients treated adjuvantly to guide dose 
adjustments with the aim of targeting mitotane concentrations of therapeutic relevance while 
avoiding severe toxicity. Experience with mitotane before availability of drug monitoring was 
afflicted by severe and disabling toxicity (15). In Europe, mitotane monitoring is readily available 
as a free service provided by the company distributing mitotane (info@lysodren-europe.com). Thus, 
this is no longer a barrier to optimal practice.  
Mitotane is a toxic drug and unwanted effects are observed in almost all patients, but toxicity is 
usually mild and tolerable, if managed properly, with a low-dose schedule. Most commonly, 
patients complain of gastrointestinal manifestations, such as nausea and diarrhea, early in the course 
of treatment. These unwanted effects occur independently on mitotane levels. They can be managed 
with temporary dose reduction, or delay of dose increments, and symptomatic therapy (1, 17).  
Clinically significant liver toxicity is characterized by a marked increase in transaminases and 
bilirubin, but is infrequently observed although predisposing conditions are present. Conversely, 
elevation in GGT levels is an universal finding without any clinical impact unless values are 
exceedingly elevated. Central neurologic toxicity is more closely associated with mitotane 
concentrations >20 mg/l but subtler symptoms, such as memory impairment or attention deficit, 
may be observed in some patients at lower concentrations (1, 17). A great individual variability in 
the susceptibility to mitotane-related unwanted effects is apparent for causes that are still unknown 
(1-3, 17, 40). Recent data from our group suggest that individual response to mitotane, in terms of 
circulating drug levels, is at least partially genetically determined (41). Evaluation of gene 
polymorphisms involved in mitotane metabolism, like CYP2B6 and ABCB1 genes, may allow 
predicting which patients may be more responsive and/or more prone to unwanted effects. 
Because of the adrenolytic effect of mitotane, all patients should receive glucocorticoid 
replacement to prevent adrenal insufficiency. Hydrocortisone (Cortisone acetate) is used at doses 
that are almost double than in Addison’s disease, due to an enhanced metabolic clearance rate of 
glucocorticoids induced by mitotane (1-3). Mitotane enhances cytochrome P450 3A4 enzyme 
activity resulting in rapid inactivation of more than 50% of administered hydrocortisone (42). An 
inadequate treatment of adrenal insufficiency increases mitotane-related toxicity, particularly 
gastrointestinal side-effects, and reduces tolerance. Adequacy of replacement has to be judged  
mostly on clinical grounds and routine biochemical tests; hormone monitoring is of limited utility 
(17). Mineralocorticoid supplementation is not mandatory in all patients because mitotane has only 
a limited effect on the zona glomerulosa. Frank elevation of PRA heralds mineracolorticoid  
insufficiency (17, 40). In mitotane-treated patients, a derangement in thyroid function characterized 
by low FT4 levels without a compensatory rise in TSH is frequently observed early in the course of 
treatment. This finding usually prompts thyroxin replacement (40). In vitro evidence that mitotane 
is able to inhibit TSH secretion at the pituitary level, thus explaining a hormone pattern alike central 
hypothyroidism, has been published (43). 
Gonadal function is also compromised during mitotane treatment by mechanisms that are still to 
be completely elucidated. Most women maintain regular cycles and may even become pregnant on 
treatment. However, some women develop ovarian cysts and olygomenorrhea with possible vaginal 
bleedings. In treated men, sexual dysfunction is more common due to inhibition of testosterone and 
DHT synthesis (40, 42). Gynecomastia is also frequently seen and may be partially due to the weak 
estrogen-like activity of mitotane (40). Sex steroid replacement may become necessary to treat 
erectile dysfunction in some patients but may worsen gynecomastia. However, the best way to 
replace gonadal steroids remains disputed (42). 
Patients should be carefully informed of the goals of treatment, including the importance to 
target mitotane concentrations of 14–20 mg/l, to motivate them to cope with unwanted effects and 
to remain compliant with a cumbersome poly-pharmacologic regimen. To this aim, it is important 
the establishment of a close patient–physician relationship to induce and maintain adherence to 
treatment. Patients may seek advice frequently and their local physicians are usually unfamiliar with 
mitotane; thus, it is necessary to give timely counseling to keep patients on treatment.  
There are insufficient data to define what is the optimal duration of adjuvant mitotane treatment. 
In our practice, we are currently recommending longer periods of treatment, at least in patients 
showing a good compliance, the minimal duration of treatment being 2 years. Since most ACC 
recurrences occur within 5 years from surgery, this period is considered as a landmark to consider 
discontinuation of treatment. 
 
MANAGEMENT OF ACC PATIENTS WITH ADVANCED DISEASE 
 
Background 
The management of patients with recurrent and metastatic disease is challenging and the 
prognosis if often poor. However, a minority of patients with metastatic disease may show a rather 
indolent disease course. Several prognostic factors such as time since diagnosis, presence of hepatic 
or bone metastases, number of metastatic lesions and number of tumoral organs involved, high 
mitotic rate (20 per 50 high-power field), and atypical mitoses in the primary tumor have been 
found to  predict survival in patients with metastatic ACC (44, 45). Two previous reports identified 
cortisol secretion as a negative prognostic factor in metastatic ACC patients. In a large single-
institution French series including 202 patients with different disease stages, cortisol excess was 
found to be an independent prognostic factor for OS and was predictive of subsequent metastatic 
disease in the subset of patients with stage I to III (46).  Similar results were obtained from a series 
of 72 Italian patients with metastatic ACC submitted to chemotherapy with EDP (Etoposide, 
Doxorubicin and Cisplatin) plus mitotane (47).   
The treatment of advanced/metastatic patients include loco-regional approaches such as surgery 
and radiofrequency ablation (RFA) in addition to systemic therapies. In presence of isolated loco-
regional recurrence or oligo-metastatic disease, surgery can lead to improved survival (14), so an 
aggressive surgical approach to achieve complete resection (R0) may be advisable. Conversely, 
tumor debulking offers little benefit and may be considered in patients with functional tumors not 
controlled by medical treatment.  
In patients who are not candidates for surgery, percutaneous image-guided RFA is a locally 
effective treatment. RFA was well tolerated in a small series of 15 ACC recurrences, with 53% of 
patients demonstrating decrease in tumor size or loss of enhancement on imaging (48). RFA in 
combination with surgical resection may allow better disease control in the setting of olygo-
metastatic disease.  
 
Chemotherapy and mitotane in the management of metastatic ACC 
Systemic  treatments in the management of patients with metastatic disease include mitotane 
alone or mitotane in combination with chemotherapy.  Single agent mitotane has a modest activity 
and response rates between 13% and 31% have been reported (Table 1). Most of the responses are 
of limited duration, and complete responses rarely occur. Monitoring mitotane serum levels is 
mandatory since it was demonstrated that disease responses are mainly confined in patients 
attaining and maintaining over time serum levels within the therapeutic range (14-20 mg/l) (34, 35). 
Mitotane serum levels within the therapeutic range are also predictive of prolonged survival (36).  
Beside of its antitumor effect, mitotane is a strong inhibitor of adrenal steroidogenesis and it has a 
compelling indication in patients with endocrine symptoms, although the rate of success in 
controlling hormone excess is not well known (2, 3). Owing to the latency of mitotane to attain the 
therapeutic range, mitotane monotherapy is indicated in the management of patients with a low 
tumor burden and/or more indolent disease. For patients whose disease show an aggressive 
behavior, cytotoxic chemotherapy is required (Figure 2). 
Whether cytotoxic chemotherapy is effective or not in the management of ACC was a matter of 
debate for a long time. The results of several small studies have demonstrated that chemotherapy 
administered alone has a limited activity and the combination of chemotherapy with mitotane seems 
to increase the response rate (Table 2). Mitotane may have a synergistic effect on chemotherapy 
activity thanks to the ability to reverse multidrug resistance mediated by P-glycoprotein expression 
(49). ACC produces high levels of the multidrug resistance protein MDR1 (also known as P-
glycoprotein) which functions as an ATP-dependent drug efflux pump, transporting out of the cell 
hydrophobic cytotoxic agents such as doxorubicin, vinblastine, and paclitaxel. However, the effect 
of mitotane on multidrug resistance has been questioned (50). 
The efficacy of chemotherapy was demonstrated by the results of a large prospective multicenter 
multinational phase III study (FIRM-ACT) that compared the efficacy of 2 chemotherapy regimens: 
Etoposide, Doxorubicin, Cisplatin, and Mitotane (EDP-M) and Streptozotocin and Mitotane (Sz-M) 
(51). Three hundred and four patients were prospectively enrolled in about 6 years. Patients with 
disease progression to the first-line treatment received the alternate regimen. EDP-M was superior 
to Sz-M both in terms of disease response rate and progression free survival (PFS). Analysis of OS 
also favored patients initially randomized to receive EDP-M but the difference just failed to attain 
statistical significance. The explorative analysis performed in the subset of patients that crossed to 
the alternative regimen upon progression showed a significant improvement of  PFS and OS in 
patients receiving EDP-M in second line as opposed to those receiving Sz-M. Therefore, the  
efficacy of EDP plus mitotane as second-line therapy attenuated its advantage as first-line therapy 
and affected the OS results. These limitation notwithstanding, it should be noted that the 5-year 
survival increased from about 7% in patients initially  randomized to receive Sz-M to about 15% in 
patients receiving EDP-M.  On the basis of the results of this trial, the European Society for 
Medical Oncology guidelines recommend EDP-M as the first-line therapy for ACC requiring 
cytotoxic therapy (6). The EDP-M regimen however is quite toxic and the combination of cisplatin 
plus mitotane may constitute a reasonable alternative for patients that appears to be not fit for EDP-
M.   
The efficacy of chemotherapy plus mitotane is overall modest but highly variable among 
patients. At our center, we treated with chemotherapy plus mitotane (mainly EDP-M) 180 
metastatic ACC patients over 20 years, and 4 of them (2.2%) obtained an extremely favorable 
outcome. All of them had a PFS greater than 5 years and only one had a disease progression after 
6.5 years, the remaining patients are still alive and disease free after 11, 5 and 6  years, respectively. 
Two patients attained a complete response and the remainders attained a partial response and then 
became disease free after surgical removal of the residual disease (52). These data suggests that 
cytotoxic therapy plus mitotane could potentially cure few metastatic ACC patients. These data 
undeline the importance to identifying factors that may predict chemotherapy efficacy in order to 
select patients for this aggressive strategy and avoid unhelpful toxicity in patients not destined to 
obtain any benefit. 
The results of second-line therapy in patients with disease progression to platinum containing 
regimens plus mitotane were as a whole modest and in most studies disappointing (see the 
following  chapter). 
Our group has developed a metronomic schedule of cytotoxic drugs in order to overcome drug 
resistance and limit patient toxicity. Metronomic chemotherapy is the administration of cytotoxic 
drugs at low doses, on a frequent or continuous schedule, with no extended interruption. This 
approach can target tumor cells indirectly, since it can affect the endothelium of the growing tumor 
vasculature and stimulates anticancer immune response. One multicenter Italian study assessed the 
activity of the combination of gemcitabine administered on day 1 and 8 in association with 
fluoropyrimidines, such as 5-fluorouracil and capecitabine, administered on a metronomic schedule 
(53). Since the main goal of metronomic approach is to induce tumor dormancy, both tumor 
response and disease stabilization (the so called clinical benefit) were considered. Among the 28 
patients who entered the study, 13 (46.4%) obtained a clinical benefit lasting 4 months at least. Two 
patients attained a tumor response according to RECIST criteria, one of them complete. The patient 
who attained a complete response remained free from progression for 48 months, then tumor 
progressed and the patient died 6 months later. These data suggest that this combination regimen 
may have some efficacy, at least in a subset of patients. Since all patients had progressive ACC to 
platinum containing regimens plus mitotane, gemcitabine plus capecitabine could be potentially 
considered non-cross resistant to cisplatin-containing regimens. Despite all patients included in the 
trial had disease progression on mitotane, the drug was not interrupted. Patients who had serum 
mitotane above the therapeutic threshold had a better time to progression than those who did not. 
These data suggest that the synergism between mitotane and chemotherapy can persist when further 
chemotherapeutic agents are introduced. This hypothesis deserve further study because practice 
varies as to continuing mitotane after progression to this treatment.  
Metronomic chemotherapy may be occasionally active also when administered after several 
treatment lines. We recently described two cases with metastatic ACC with a rather long disease 
history that attained a durable disease response with oral cyclophosphamide and oral etoposide, 
respectively, both administered on a metronomic schedule (54). These data suggest that metronomic 
chemotherapy may be active in patients bearing a rather indolent disease.   
 
Molecular target agents in the management of metastatic ACC 
Several oncogenes, growth factors and tumor suppressor genes have been implicated in ACC 
tumorigenesis. The most important genomic alterations involve the p53 system, the Insulin Growth 
Factor Receptor (IGFR) and the Wnt/-catenin signalling  pathway. In addition, also the Epidermal 
Growth Factor Receptor (EGR) and neoangiogenesis are considered potential targets.  
As outlined in Table 3,  several small phase II trials have tested the efficacy of molecular agents 
targeting EGFR, angiogenesis, IGFR, and mTOR pathways. These treatments were administered in 
pre-treated patients. The molecular agents employed were tested alone, in combination with 
chemotherapy, or with other molecular target agents. As a whole, these trials obtained poor results. 
EGFR target agents (gefitinib and erlotinib) either administered alone, or in combination with 
gemcitabine, were not active (55, 56). Three trials tested anti-angioenetic drugs, two of them testing 
the association of bevacizumab with capecitabine (57) and sorafenib with weekly paclitaxel (58), 
respectively, led to negative results. In a multicenter prospective phase II German trial, sunitinib 
obtained disease stabilization lasting more than 4 months in 5 patients out of the 36 consecutively 
enrolled (13.8%); 4 of them showed a modest increase of ACC lesions less than 20% and therefore 
below the threshold for progression according to the RECIST criteria and only one a decrease of 
tumor burden (below the threshold of response) (59).  
The reasons why these trials were substantially negative are not clear and several hypotheses can 
be raised. First, poor patients selection, because of i) inclusion of heavily pretreated cases that may 
have led to emerging of multi-resistant tumor clones, or ii) inclusion of tumor that do not express 
the molecular target. As an example, EFR mutations in ACC are extremely rare and this may have 
accounted for the poor response obtained with the EGFR inhibitors in unselected ACC patients. It 
has been shown that these drugs are active in the small subset of patients whose non small cell lung 
cancers harbor EGFR mutation (60). Second, the patients included in molecular target therapy trials 
were pretreated with mitotane, a drug with a very long half life (more than 40 days) and whose 
biological activity usually persists for months after drug withdrawal. Many small molecular target 
agents are substrates of the p450 dependent enzyme CYP3A4 that is induced by mitotane (61). 
Therefore, pretreatment with mitotane may have reduced the antitumor efficacy of these agents.  
Better results were obtained by figitumumab, a monoclonal antibody against IGFR-1, either 
administered alone (62) or in combination with the mTOR inhibitor temsirolimus (63, 64). As 
shown in Table 3, durable disease stabilizations were obtained in a relevant proportion of patients. 
In our opinion, figitumumab deserves to be further explored in the management of advanced ACC. 
Being a monoclonal antibody, this drug is not metabolized by the CYP3A4 enzyme and its 
pharmacokinetic may be not negatively influenced by mitotane. A prospective phase II trial testing 
the activity of  figitumumab in association with mitotane in ACC relapsed/refractory or primary not 
removable by surgery is currently recruiting in USA (Trial No NCT00778817).   
The most important study in this arena was a multicenter, multinational, prospective, 
randomized, placebo-controlled clinical trial recently conducted aimed to test the efficacy of OSI 
906–301, a small molecule IGFR inhibitor, as second- /third-line approach in advanced/metastatic 
ACC patients (Trial No: NCT00924989). This trial has completed patient accrual in June 2011 and 
the final results are expected in 2014.  
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Figure 1.  Management strategies following surgical extirpation of ACC. 
 
Figure 2.  Management strategies of patients with advanced ACC. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
